At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 26 enrolled
Drug / intervention
Afliberceptdrug
Likely dose
Aflibercept 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
In Brief
A Phase 4 clinical trial evaluating Aflibercept for Exudative Macular Degeneration. Completed, enrolled 26 participants across 1 site.
Detailed Summary
This study will examine the use of Aflibercept in patients with exudative macular degeneration requiring intravitreal injections. Patients will be followed for 24 months. The follow up phase will be completed at month 36.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExudative Macular Degeneration
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedJun 2012
Primary CompletionDec 2013
Study CompletionDec 2015
TodayJul 2026
First PostedJun 12, 2012
Enrollment StartJun 1, 2012
Primary CompletionDec 1, 2013
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.1 years ago
Interventions
Afliberceptdrug
Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.